ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer
| Title: | ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer |
|---|---|
| Authors: | Planchard, D. 1, ∗; Reinmuth, N. 2; Orlov, S. 3; Fischer, J.R. 4; Sugawara, S. 5; Mandziuk, S. 6; Marquez-Medina, D. 7; Novello, S. 8; Takeda, Y. 9; Soo, R. 10; Park, K. 11; McCleod, M. 12; Geater, S.L. 13; Powell, M. 14; May, R. 14; Scheuring, U. 15; Stockman, P. 15; Kowalski, D. 16 |
| Source: | In Annals of Oncology May 2020 31(5):609-618 |
| Database: | ScienceDirect |